Navigation Links
Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Date:11/1/2009

hronic hepatitis C in patients 3 years of age and older with compensated liver disease.

The following points should be considered when initiating therapy with PEGINTRON in combination with REBETOL: (1) These indications are based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. (2) Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. (3) No safety and efficacy data are available for treatment of longer than one year.

PEGINTRON is also indicated for use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age.

The following points should be considered when initiating therapy with PEGINTRON alone: Combination therapy with REBETOL is preferred over PEGINTRON monotherapy unless there are contraindications to, or significant intolerance of, REBETOL. Combination therapy provides substantially better response rates than monotherapy.

Important Safety Information on PEGINTRON

WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy.

Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Canary Foundation Commits to Supporting New Platform for Cancer Diagnostics
2. Food 4 Less Stores Giving Hope a Hand(R) in October by Supporting Breast Cancer Awareness Initiatives
3. Ralphs Stores Giving Hope a Hand(R) in October by Supporting Breast Cancer Awareness Initiatives
4. AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve
5. Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Associations Family Link Program In Connecticut
6. livethesource(TM) Hosts Company Launch Event While Supporting The Brent Shapiro Foundations Annual Sober Night Out
7. CMSA Announces New Model ACT Supporting Case Management Programs
8. Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness, Grief and Loss
9. The Sensory Research Center (SRC) Offers 2 for 1 Tickets for Benefit Concert Supporting Autism, Downs Syndrome, Cerebral Palsy and Other Disabilities.
10. Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform
11. American Humane Association Launches Innovative Therapy Animals Supporting Kids (TASK)(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 30, 2015 “ Milli the Snail ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... game that engages and educates children. , Interactive mobile games ... all the content and games they are playing are doing ...
(Date:5/29/2015)... “In the current environment of opiate ... we provide education that will help practitioners address ... from pain, within the boundaries of the guidelines ... rehabilitation medicine and President/Medical Director of the International ... A new flight of PAINWeekEnd Regional Conferences offers ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the “ ... now offers The Smartest Rheumatologist . The Smartest ... ranging from Fibromyalgia and Osteoporosis, to Arthritis and Gout. ... and Caroline Tredway, editorial head of The Smartest Doc ... on the physicians who participate. Says Tredway, “With so ...
(Date:5/29/2015)... The science of Follicular Unit Extraction (FUE) ... efficient methods of FUE hair transplantation have increased the amount ... most cutting edge hair transplant methods being used to great ... extracting hair from the beard to the scalp. , Most ... male pattern baldness. Beard hair has a life cycle, ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her ... else: God does no wrong. , It’s fitting, then, that ... is titled “God Does No Wrong.” It focuses on what ... tragedy. , “My story has a positive message about ... something productive, something healing,” Howse said. , “God Does No ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2
... THRM ), a leader in non-invasive tissue ... will present at the 2008 Maxim Group,Growth Conference. ... Time on Tuesday, October 7, 2008. Stephen J. ... the company,s business,strategy and historical financial results., ...
... Share Exchange Offer to the Holders of the Following Securities, ... JNJ, The K&N Value Select Corporation offers the holders of ... change into 1 share of,K&N Value Select Corp. - ISIN: CH0006603085 ... October 2008 and ends on 27th November,2008., K&N Value Select ...
... pleased to recognize the Association for Healthcare Resource and Materials ... 5-11. This week is dedicated to acknowledging and celebrating ... healthcare and the overall success of the healthcare supply chain. ... ...
... System To Reduce Claim Fraud and Costs by ... ILOG(R) (Nasdaq:,ILOG, Euronext: ILO, ISIN: FR0004042364) today announced ... in Argentina, is using ILOG,JRules(R) to automate its ... Swiss Medical has been able to reduce,unnecessary medical ...
... often seasonal allergy that affects between 10 and 20 ... a course of patient-adjusted dosing, according to new research ... Head and Neck Surgery. , During the ... allergic rhinitis, was observed in 69 patients, who were ...
... than 1 million children, Stores raise funds for Vitamin ... Quarters found in the,bottom of purses, pockets, and even on ... needy children. The Vitamin Shoppe is asking,everyone to donate their ... a,child., Affecting up to 140 million children every year, ...
Cached Medicine News:Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 2Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 3Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 2Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 3Health News:Hay fever may be best treated with self-adjusted dosing 2Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: